scholarly journals Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

2021 ◽  
Author(s):  
E F Magavern ◽  
J C Kaski ◽  
R M Turner ◽  
H Drexel ◽  
A Janmohamed ◽  
...  
Keyword(s):  
Working Group ◽  
Healthcare Delivery ◽  
Work Force ◽  
Clinical Work ◽  
Group Position ◽  
Cardiovascular Therapy ◽  
Cardiovascular Pharmacotherapy ◽  
Barriers To Implementation ◽  
Legal Frameworks ◽  
European Society Of Cardiology

Abstract Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on PGx implementation. Clinical work force upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.

scholarly journals Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology

2017 ◽  
Vol 114 (1) ◽  
pp. 19-34 ◽  
Author(s):  
Joost Petrus Gerardus Sluijter ◽  
Sean Michael Davidson ◽  
Chantal M Boulanger ◽  
Edit Iren Buzás ◽  
Dominique Paschalis Victor de Kleijn ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Working Group ◽  
Position Paper ◽  
Paracrine Effects ◽  
Group Position ◽  
Wide Range ◽  
Potential Alternative ◽  
Number Of Publications ◽  
European Society Of Cardiology ◽  
Regenerative Therapies

AbstractExtracellular vesicles (EVs)—particularly exosomes and microvesicles (MVs)—are attracting considerable interest in the cardiovascular field as the wide range of their functions is recognized. These capabilities include transporting regulatory molecules including different RNA species, lipids, and proteins through the extracellular space including blood and delivering these cargos to recipient cells to modify cellular activity. EVs powerfully stimulate angiogenesis, and can protect the heart against myocardial infarction. They also appear to mediate some of the paracrine effects of cells, and have therefore been proposed as a potential alternative to cell-based regenerative therapies. Moreover, EVs of different sources may be useful biomarkers of cardiovascular disease identities. However, the methods used for the detection and isolation of EVs have several limitations and vary widely between studies, leading to uncertainties regarding the exact population of EVs studied and how to interpret the data. The number of publications in the exosome and MV field has been increasing exponentially in recent years and, therefore, in this ESC Working Group Position Paper, the overall objective is to provide a set of recommendations for the analysis and translational application of EVs focussing on the diagnosis and therapy of the ischaemic heart. This should help to ensure that the data from emerging studies are robust and repeatable, and optimize the pathway towards the diagnostic and therapeutic use of EVs in clinical studies for patient benefit.

scholarly journals Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

2019 ◽  
Vol 5 (3) ◽  
pp. 171-180 ◽  
Author(s):  
Patrick Sulzgruber ◽  
Sven Wassmann ◽  
Anne Grete Semb ◽  
Wolfram Doehner ◽  
Petr Widimsky ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
European Society ◽  
Oral Anticoagulation ◽  
Working Group ◽  
Thromboembolic Risk ◽  
Current Opinion ◽  
Cardiovascular Pharmacotherapy ◽  
Therapeutic Decisions ◽  
The Individual ◽  
European Society Of Cardiology

Abstract Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

Sign in / Sign up

Export Citation Format

Share Document